Arrow
Arrow
Slider

Premaitha Health PLC
(“Premaitha” or the “Company”)

Southern Europe Business Update

Manchester, UK – 7 February 2017: Premaitha Health PLC (AIM: NIPT), developer of a leading CE-marked non-invasive prenatal screening system, announces a number of new customers through its distribution network in Southern Europe.

Italy
Premaitha’s Italian distributor has won a public hospital tender to implement the first public non-invasive prenatal testing (“NIPT”) programme in southern Italy. The hospital will act as a regional hub and is expected to be ready for processing routine samples using the IONA® test in early Q2 2017.

In addition, a second Italian laboratory has completed the installation phase and has begun processing small volumes of the IONA® test in Rome with the potential to ramp up as awareness of the availability of NIPT further permeates the Italian healthcare system.

Greece and Balkans
Premaitha’s distributor for Greece has signed a contract to establish the IONA® test in a laboratory in northern Greece which will act as a hub for processing samples from around Greece and the Balkans. The customer has been channelling NIPT samples to another European service provider and therefore already has established a network of feeder clinics. The laboratory is expected to be operational with the IONA® test by the end of Q1 2017.

Turkey
Premaitha has won a new service-laboratory customer in Turkey, sending samples for processing in the Company’s own laboratory in Manchester, UK. Volumes for this new territory are expected to be small initially with substantial scope for growth in this emerging NIPT market.
    
Premaitha’s IONA® test estimates the risk of a fetus being affected with Down’s syndrome or other genetic conditions. The test is performed on the mother’s blood sample, containing traces of fetal DNA, which is then analysed using next generation DNA sequencing technology. The test is highly accurate and significantly reduces the number of women who are unnecessarily subjected to risky, invasive follow up procedures to diagnose Down’s syndrome and other genetic conditions.
    
Dr Stephen Little, CEO of Premaitha Health, commented: “We are working hard to establish a network of like-minded distribution partners. The IONA® test is designed specifically to support the dissemination of genetic testing, and we are now seeing real evidence of this happening in Europe.”

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

For more information, please contact:

Premaitha Health PLC
Dr Stephen Little, Chief Executive Officer    
Barry Hextall, Chief Financial Officer    
This email address is being protected from spambots. You need JavaScript enabled to view it.
Tel: +44 (0) 161 667 6865

Cairn Financial Advisers LLP (Nomad)
Liam Murray / Jo Turner    
Tel: +44 (0) 20 7213 0880
    
finnCap (Broker)
Adrian Hargrave / Scott Mathieson (Corporate Finance)    
Tony Quirke (Corporate Broking)    
Tel: +44 (0) 20 7220 0500
    
Vigo Communications
Ben Simons / Fiona Henson / Antonia Pollock    
This email address is being protected from spambots. You need JavaScript enabled to view it.
Tel: +44 (0) 20 7830 9700

About Premaitha
Premaitha is a molecular diagnostics company which uses the latest advances in DNA analysis technology to develop safer, faster and regulatory approved non-invasive screening tests for pregnant women.

Premaitha’s lead test – the IONA® test – was launched in February 2015 and is the leading CE marked complete system which estimates the risk of a fetus being affected with Down’s syndrome or other genetic conditions. The IONA® test is performed on the mother’s blood sample - which contains traces of fetal DNA - and then analysed using next generation DNA sequencing technology from ThermoFisher Scientific.

Unlike existing prenatal screening methods, due to its high level of accuracy, the IONA® test can significantly reduce the number of women subjected to unnecessary stressful and invasive follow up diagnostic procedures which are costly, resource intensive and carry a risk of miscarriage.

Non-invasive prenatal screening is an emerging, multi-billion dollar global market and Premaitha’s complete CE Marked system enables laboratories and health care practitioners to offer an approved, non-invasive prenatal screening system in-house.  

Premaitha is based in Manchester Science Park, United Kingdom and its shares trade on the AIM market of the London Stock Exchange (AIM: NIPT). For further information please visit www.premaitha.com. Follow us on twitter @PremaithaHealth.

  • 13 March 2017 - Premaitha Raises Awareness of the IONA® Test at Key International Medical Events +

    Premaitha Health PLC
    (“Premaitha” or the “Company”)

    Premaitha Raises Awareness of the IONA ® Test at Key International Medical Events

    Manchester, UK – 13 March 2017: Premaitha Health PLC (AIM: NIPT), a leading international molecular diagnostics group focused on prenatal testing, will be attending a series of key international fetal medicine and OB/GYN events during March to broaden awareness of the IONA ® test. The events will include:

    The Royal College of Obstetricians and Gynaecologists

    Read More
  • 27 February 2017 - Completion of Yourgene Acquisition, Issue of Shares and Director Appointments +

    Premaitha Health PLC
    (“Premaitha” or the “Company” or the “Group”)

    Completion of Yourgene Acquisition, Issue of Shares and Director Appointments

    Manchester, UK – 27 February 2017: Premaitha Health PLC (AIM: NIPT), a leading international molecular diagnostics group focused on prenatal testing, announces regulatory clearance for the completion of the acquisition of Yourgene Bioscience Co., Ltd (“Yourgene”).

    The acquisition of Yourgene, announced on 21 December 2016, has now received regulatory clearance as required by Taiwanese law. 

    Read More
  • 20 February 2017 - Middle East Business Update +

    Premaitha Health PLC
    (“Premaitha” or the “Company”)

    Middle East Business Update

    Manchester, UK – 20 February 2017: Premaitha Health PLC (AIM: NIPT), developer of a leading CE-marked non-invasive prenatal screening system, is pleased to announce significant commercial progress in the Middle East through its distribution network.

    Premaitha has appointed distributors across the Middle East and these partners have signed a number of new Middle Eastern customers which in aggregate are expected to generate over 10,000

    Read More
  • 16 February 2017 - Publication of scientific paper on Premaitha’s IONA® test +

    Premaitha Health PLC
    (“Premaitha” or the “Company”)

    Publication of scientific paper on Premaitha’s IONA ® test

    Manchester, UK – 16 February 2017 : Premaitha Health, developer of a leading CE-marked non-invasive prenatal screening system, is pleased to announce the publication of “ The IONA® Test: Development of an Automated Cell-Free DNA-Based Screening Test for Fetal Trisomies 13, 18, and 21 That Employs the Ion Proton Semiconductor Sequencing Platform ” in Fetal Diagnosis and Therapy.

    The paper

    Read More
  • 15 February 2017 - Issue of Equity +

    Premaitha Health plc
    ("Premaitha" or the "Company")

    Issue of Equity

    Manchester, UK - 15 February 2017: Premaitha Health plc (AIM: NIPT), developer of a leading CE-marked non-invasive prenatal screening system, announces that it has agreed to issue to Harwood Capital ("Harwood") 17,000,000 new ordinary shares of 0.1 pence per share, subject to admission to AIM, raising £1,487,500 at a price of 8.75 pence per share. Following the allotment of the shares, Harwood's holding will represent 6.9%

    Read More
  • 13 February 2017 - New partnership with major European diagnostics group +

    Premaitha Health PLC
    (“Premaitha” or the “Company”)

    New partnership with major European diagnostics group

    Manchester, UK – 13 February 2017: Premaitha Health PLC (AIM: NIPT), developer of a leading CE-marked non-invasive prenatal screening system, announces a partnership with a major international diagnostics services group to implement the IONA ® test in at least two laboratories.

    Premaitha, through its distribution network, has secured a four-year Master Procurement Agreement (the “MPA”) with a major European diagnostics services

    Read More
  • 7 February 2017 - Southern Europe Business Update +

    Premaitha Health PLC
    (“Premaitha” or the “Company”)

    Southern Europe Business Update

    Manchester, UK – 7 February 2017: Premaitha Health PLC (AIM: NIPT), developer of a leading CE-marked non-invasive prenatal screening system, announces a number of new customers through its distribution network in Southern Europe.

    Italy
    Premaitha’s Italian distributor has won a public hospital tender to implement the first public non-invasive prenatal testing (“NIPT”) programme in southern Italy. The hospital will act as a regional hub

    Read More
  • 21 December 2016 - Conditional Acquisition of Yourgene Bioscience and Posting of Circular +

    Issued on behalf of Premaitha Health plc
    Manchester, UK: Wednesday, 21 December 2016

    Premaitha Health PLC
    (“Premaitha” or “the Company”)

    Conditional Acquisition of Yourgene Bioscience and Posting of Circular

    Manchester, UK – 21 December 2016: Premaitha Health PLC (AIM: NIPT), developer of a leading CEmarked non-invasive prenatal screening system (“NIPT”), announces the conditional acquisition of Yourgene Bioscience Co., Ltd (“Yourgene”) (the”Acquisition”), a significant NIPT provider in Asia and the posting shortly of a circular convening

    Read More
  • 21 December 2016 - Half Year Results +

    Issued on behalf of Premaitha Health plc
    Manchester, UK: Wednesday, 21 December 2016

    Premaitha Health PLC
    (“Premaitha” or “the Company”)

    Half Year Results

    Manchester, UK – 21 December 2016 : Premaitha Health (AIM: NIPT), developer of a leading CE-marked non-invasive prenatal screening system, announces its half year results for the six months ended 30 September 2016.

    Financial position

    • Revenues increased by 130% to £1.5m (H1 15/16: £0.6m) to a diversified international client base
    • Gross

    Read More
  • 21 November 2016 - Premaitha establishes first service laboratory customer in Asia +

    Issued on behalf of Premaitha Health plc
    Manchester, UK: Monday, 21 November 2016

    Premaitha Health PLC
    (“Premaitha” or “the Company”)

    Premaitha establishes first service laboratory customer in Asia

    the IONA ® test to be offered in the Center for Medical Genomics, Ramathibodi Hospital partnering with the Thailand Center of Excellence for Life Sciences (TCELS)

    Manchester, UK – 21 November 2016: Premaitha Health plc (AIM: NIPT), developer of the leading CE-marked complete non-invasive prenatal screening system,

    Read More
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6

Investor Relations
Ben Simons / Fiona Henson
Vigo Communications
180 Piccadilly
London W1J 9HF
premaitha@vigocomms.com
T : +44 (0) 20 7830 9700

Public Relations
Sophie Burness / Ellie Scott
Kindred Agency
4th Floor, Dean Bradley House
52 Horseferry Road
London SW1P 2AF
IONAcampaigns@kindredagency.com
T : +44 (0) 20 7830 9700

Two business people looking at computer screen